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Hepatitis C virus–related cryoglobulinemic glomerulonephri- branoproliferative glomerulonephritis with distinctive
tis: Long-term remission after antiviral therapy. histologic characteristics that is usually associated with
Background. Renal involvement in patients with hepatitis type II mixed cryoglobulinemia [1]. Although the patho-C virus (HCV) infection commonly manifests as cryoglobuli-
genesis of HCV-related CGN is still unclear, variousnemic glomerulonephritis (CGN). The combination of inter-
forms of antiviral therapy previously employed in chronicferon-alpha (IFN-) and ribavirin, which is currently consid-
ered the standard antiviral therapy in chronic hepatitis C, could hepatitis C have been recently suggested by several au-
be difficult to carry out in cryoglobulinemic patients who are thors. A beneficial effect of treatment with interferon-
frequently anemic, even in the absence of renal failure. Clinical
(IFN-) [2–5], ribavirin [6, 7], or both in combination [8, 9]and histologic long-term results of this therapeutic regimen
has been described, but a sustained response to thesehave not been so far reported in patients with CGN.
Methods. Three patients with HCV-related CGN and drugs has been rarely obtained. Moreover, evidence of
slightly impaired kidney function were treated with IFN- and improvement in histologic features of CGN has been
ribavirin for 12 months, and subsequently were followed up
reported in only isolated cases [10, 11]. We describe threefor 24 to 36 months. Two of these patients who were anemic
consecutive patients with HCV-associated CGN whowere pretreated with erythropoietin (EPO). In each patient
renal biopsy was performed before starting therapy and re- achieved a long-term clinical and histologic remission
peated 14 to 26 months after the end of treatment. following a combined antiviral treatment with IFN- and
Results. In all three patients, antiviral therapy induced sus- ribavirin.tained virologic response, which was followed by clear improve-
ment in clinical, biochemical, immunologic, and histologic fea-
tures. Clinical and biochemical improvement steadily progressed
METHODSin all three patients, achieving normal or nearly normal results
at the end of follow-up. In contrast, some immunologic fea- Patients
tures, such as serum levels of C4 and rheumatoid factor activity,
Patient 1 was a 58-year-old woman with a 10-year his-did not normalize in two and three patients, respectively. Post-
tory of leg purpura and arthralgia. In 1993 a diagnosistreatment renal biopsies showed mildly active histologic le-
sions. of HCV-related type II (IgG-IgM kappa) mixed cryoglo-
Conclusion. Antiviral therapy with IFN- and ribavirin may bulinemia was established. At that time, no manifestation
be considerably beneficial in patients with HCV-related CGN
of renal disease was noted. She received two courseswho obtain sustained virologic response.
of IFN- therapy during a 2-year period, but no clear
response could be observed. In 1996, she developed ne-
phrotic syndrome and underwent renal biopsy that re-The most common expression of renal involvement in
vealed the characteristic lesions of CGN. She obtainedpatients with hepatitis C virus (HCV) infection is cryo-
only slight and temporary improvement in the manifesta-globulinemic glomerulonephritis (CGN). This is a mem-
tions of renal disease after treatment with corticosteroids
and cyclophosphamide. The patient was referred to ourKey words: hepatitis C virus, cryoglobulinemia, glomerulonephritis,
interferon-, ribavirin. unit in August 1997.
Patient 2 was a 60-year-old man who reported a long-
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HCV testing and a liver biopsy demonstrated features All three patients required antihypertensive medica-
consisting with the diagnosis of chronic hepatitis C. Uri- tions, including angiotensin-converting enzyme (ACE)
nary protein excretion was 5.1 g/day and serum creati- inhibitors and diuretics during both the periods of antivi-
nine was 115 m/L. Renal biopsy disclosed a membrano- ral treatment and posttreatment follow-up.
proliferative glomerulonephritis. The presence in the
Evaluation of therapeutic responseserum of mixed cryoglobulins (IgG-IgM kappa) led to diag-
nosis of CGN. He was treated initially with corticosteroids The patients were seen as outpatients every 2 weeks
(25 mg prednisone) and subsequently with IFN-2b 5 mil- for 8 weeks, and then at 4-week intervals during the
lion units 3 times a week for 6 months. IFN- therapy treatment period. Subsequently the patients were fol-
produced a transient normalization of alanine amino- lowed-up every 6 months for 24 to 36 months. At each
transferase in the absence of virologic response, whereas visit, renal and extrarenal manifestations of mixed cryo-
the manifestations of renal disease remained essentially globulinemia, along with the side effects of therapy, were
unchanged. The patient was referred to our unit in Octo- carefully evaluated.
ber 1997. The changes of kidney disease were monitored by
Patient 3 was a 35-year-old man who was admitted means of clinical signs (edema, hypertension) and labo-
to our hospital in May 1998 for evaluation of severe ratory tests (proteinuria, albuminemia, and creatinine
hypertension first noted 2 months earlier and unrespon- clearance). In addition, the three patients underwent a
sive to 100 mg atenolol. On admission, the patient pre- first renal biopsy before starting antiviral therapy and a
sented ankle edema, hypertension (190/120 mm Hg), second one 14 to 26 months after the end of treatment
moderate proteinuria (2.7 g/day), mild renal insufficiency period.
(serum creatinine 134 m/L) and positive serum testing A variety of clinical symptoms and signs, such as ar-
for HCV antibodies and HCV RNA. Moreover, the pres- thralgia and purpura, blood counts, and biochemical tests
ence of type II mixed cryoglobulins (IgG-IgM kappa) served as indicators of extrarenal involvement and ad-
was demonstrated in his serum. Renal biopsy findings verse drug reactions.
were consistent with the diagnosis of CGN. The levels of cryocrit, C4, and rheumatoid factor activ-
ity in the serum were used to measure the immunologicLaboratory tests
response.
Liver and kidney function tests were performed ac- To assess the virologic response, the concentration of
cording standard methods. Rheumatoid factor and com- HCV RNA in the serum was determined at fixed inter-
plement levels were measured by rate nephelometry.
vals, namely, after 4 weeks of ribavirin monotherapy,
Cryoglobulins isolated from the serum were measured
after 4 weeks of combined treatment, at the end of theas cryocrit (i.e., the percentage of packed cryoglobulins).
treatment period, and then every 6 months during theHCV antibodies were detected using a second-genera-
posttreatment follow-up.tion enzyme immunoassay (Abbott Laboratories, North
Chicago, IL, USA). Serum HCV RNA was quantified
with a commercial reverse transcriptase polymerase chain RESULTS
reaction (RT-PCR) assay (Amplicor HCV monitor, Virologic response
Roche Diagnostic System, Branchburg, PA, USA). HCV
At the start of antiviral therapy, the three patientsgenotyping was performed by PCR, using primers spe-
were HCV RNA positive, two having genotype 2b andcific for the HCV core region, as described [12].
the third one having the 2a type. After 4 weeks of ribavi-
rin monotherapy, the viremia decreased by 1.2, 1.2, andTreatment
0.2 Log/mL in the three patients, respectively. After 4The three patients received ribavirin at the initial dose
weeks of combination therapy with ribavirin and IFN-,of 15 mg/kg/day, which was adjusted to maintain hemo-
HCV disappeared from the serum of all three patients.globin values between 10 and 12 g/dL on the basis of
Afterwards, this result was confirmed at the end of treat-fortnightly measurements. After 4 weeks of ribavirin
ment period and maintained during the posttreatmentmonotherapy, IFN-2b was added at a dose of 3 million
follow-up.units three times a week, and then the combined treat-
ment was continued for 1 year. Patients 1 and 3 who
Clinical and biochemical responsepresented anemia before starting antiviral therapy were
Following 4 weeks of treatment with ribavirin alone,pretreated with erythropoietin (EPO), 10,000 UI, subcu-
no appreciable change in clinical or biochemical featurestaneously once a week until an hemoglobin value of 12
could be observed.g/dL or greater was obtained. Subsequently, EPO was
As shown in Table 1, a few months after the start ofcontinued in association with ribavirin and IFN- admin-
istered as above described. combination therapy, edema and purpura disappeared
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Table 1. Changes of clinical signs and laboratory values
Patient 1 Patient 2 Patient 3
Parameters B 6m ET FU B 6m ET FU B 6m ET FU
Edema            
Hypertension 170/90 140/80 130/85 135/85 165/90 135/80 140/80 135/80 190/120 110/80 110/80 120/80
Purpura            
Proteinuria g/day 2.4 1.6 0.3 0.1 5.3 0.4 0.8 0.1 2.7 0.7 0.5 0.3
Albuminemia g/L 30 38 39 41 24 42 43 44 35 47 46 47
Creatinine clearance mL/s 0.9 0.97 0.98 1.13 0.88 0.93 1.37 1.35 1.12 1.75 1.87 1.98
Cryocrit % 3 2   2 1   1.5   
C4 g/L 0.05 0.06 0.12 0.12 0.09 0.24 0.27 0.23 0.03 0.08 0.10 0.12
Rheumatoid factor UI/ml 210 156 149 112 2142 461 425 99 1320 603 385 266
Abbreviations are: B, baseline values; 6m, 6 months of treatment; ET, end of treatment; FU, end of follow-up; , absent or undetectable; , mild; , moderate;
, marked.
Normal values are proteinuria, 0.15 g/day; albuminemia, 3.5 g/L; creatinine clearance, 1.25 to 2.08 mL/s; cryocrit, undetectable; C4, 0.15 to 0.40 g/L; rheumatoid
factor, 20 UI/mL.
Table 2. Renal biopsy findings
Patient 1 Patient 2 Patient 3
Light microscopy FB SB FB SB FB SB
Mesangial matrix      
Mesangial cells      
Monocyte infiltration      
GBM thickening and double contours      
Vasculitis      
Immunofluorescence
Subendothelial deposits IgM IgM IgM IgM IgM IgM
C3 C3 C3 C3
Mesangial deposits IgM IgM IgM IgM IgM IgM
C3 C3 C3 C3
Electron microscopy
Mesangial matrix      
Mesangial cells      
Monocyte infiltration      
Subendothelial deposits      
Mesangial deposits      
Abbreviations are: FB, first biopsy; SB, second biopsy; GBM, glomerular basement membrane; , undetectable; , occasionally seen; , mild; , moderate;
, marked.
in all three patients. At the same time, blood pressure patients. On light microscopy, we found moderate to
normalized with reduced doses of antihypertensive drugs. severe increase in mesangial matrix, mesangial cells, and
Proteinuria decreased and creatinine clearance in- monocytes along with thickening of glomerular base-
creased regularly throughout the observation period, re- ment membrane (GBM) and formation of double con-
turning into the normal range in two patients at the end tours (Fig. 1A). Only in one case, renal vasculitis was
of posttreatment follow-up. Cryoglobulins decreased to observed. Immunofluorescence study showed diffuse
undetectable levels in the three patients before the com- glomerular deposits of IgM apparently more abundant
pletion of treatment. The serum concentration of C4 be- along the capillary walls than in mesangium Fig. 2A). In
came normal in one patient and increased to slightly two patients, deposits of C3 with similar characteristics
subnormal levels in the others. Rheumatoid factor activ- were demonstrated as well. On electron microscopy, the
ity clearly decreased in all patients, but in none of them glomerular abnormalities found on light microscopy,
achieved normal values. Hemoglobin concentration de-
such as increase in mesangial matrix, mesangial cells,creased by 2.1 to 4.5 g/dL in the three patients, necessitat-
and infiltrating monocytes, were confirmed. In addition,ing a reduction in the dose of ribavirin in one of them.
it was observed that the formation of double contoursOther side effects, such as flu-like and gastrointestinal
was mainly due to peripheral interposition of monocytessymptoms, albeit common, did not require modifications
that were in close contact with subendothelial depositsof therapy.
consisting of amorphous or variously structured material.
Renal histologic changes The second biopsy revealed obvious improvement in
renal lesions. On light microscopy, the increase of mesan-Table 2 shows that, before starting antiviral therapy,
renal histologic features were quite similar in the three gial matrix and mesangial cells was mild or occasionally
Rossi et al: Treatment of cryoglobulinemic glomerulonephritis 2239
Fig. 1. Patient 2. (A ) First biopsy. On light microscopy, the enlarged Fig. 2. Patient 3. (A ) First biopsy. Immunofluorescence study revealsglomerulus shows marked endocapillary hypercellularity. Expansion of intense glomerular deposition of IgM mainly along the capillary wallsmesangial matrix and thickening of glomerular basement membrane (magnification 250). (B ) Second biopsy. The glomerular deposits ofwith formation of double contours are also present (hematoxylin-eosin IgM appear scanty, faint, and undefined in location (magnification250).stain; magnification 250). (B ) Second biopsy. The glomerulus shows
only mild increase of endocapillary cells and expansion of mesangial
matrix (hematoxylin-eosin stain; magnification  250).
units three times a week for 6 months) has been able to
improve the renal function and/or reduce the protein-
uria, possibly as a consequence of the clearance of HCVseen (Fig. 1B). Monocyte infiltration and GBM thick-
and the disappearance of cryoglobulins from the serumening with double contours were rarely observed. Renal
[2, 3]. Unfortunately, although more favorable resultsvasculitic lesions, previously demonstrated in patient 1,
have been achieved in some patients treated with higherdisappeared. On immunofluorescence, scanty deposits
doses of IFN- [4, 10], in most cases the disease tendsof IgM were still recognizable (Fig. 2B), while those of
to recur upon discontinuation of the drug. The combina-C3 were no longer detectable in both subendothelial
tion of IFN- with the nucleoside analog ribavirin hasand mesangial locations. The electron microscopy study
recently emerged as the most effective form of antiviralconfirmed that the mass of mesangial cells and mono-
therapy in chronic hepatitis C, even though the lattercytes that had been observed on the first biopsy was
drug given alone seems unable to suppress the replica-markedly reduced. Subendothelial deposits disappeared
tion of HCV [13, 14]. Similar results have been observedin two of three patients, whereas scanty deposits were
in patients with CGN in whom the combined treatmentstill detectable in mesangium.
with IFN- and ribavirin was able to obtain a long-lasting
virologic and clinical response [8, 9], whereas ribavirin
DISCUSSION monotherapy produced some transient clinical improve-
The current knowledge of close association between ment, but not the clearance of HCV from the serum
HCV infection and mixed cryoglobulinemia, with or [6, 7]. An important limitation of ribavirin is the tendency
without renal disease, has prompted a growing use of to cause hemolytic anemia, which may require early dis-
antiviral therapy in this condition. In many patients with continuation of this drug or even preclude its use in
patients with low values of hemoglobin concentrationCGN, IFN- monotherapy at standard doses (3 millions
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[13–15]. Unfortunately, up to 70% of patients with mixed the clearance of HCV from the serum, could be related
cryoglobulinemia show normochromic normocytic ane- to the slow and incomplete regression of the above-
mia at presentation, even in the absence of renal failure mentioned immunologic abnormalities.
[16, 17]. Indeed, two of our patients had anemia with Although much encouraging, these results are not suf-
unrevealing laboratory tests and bone marrow examina- ficient evidence to propose this form of treatment in all
tion. In both cases, pretreatment with EPO enabled us to cases of HCV-related CGN. We are aware that, in pa-
start antiviral therapy with standard or slightly reduced tients with interferon resistant HCV genotypes or those
doses of ribavirin. with severe and/or rapidly progressive manifestations
In the three patients reported herein we had the op- of disease the response to antiviral therapy could be
portunity of evaluating the effects of different modalities unsatisfactory [1, 21]. Furthermore, the use of interferon
of antiviral therapy. Two of these patients had been pre- has been associated with the development of various
viously treated with IFN- alone at standard or high doses, forms of renal disease or the exacerbation of preexisting
but no appreciable benefit could be obtained. Similarly, CGN [21, 22]. In all these conditions where antiviral
4 weeks of ribavirin monotherapy did not appear to im- drugs are ineffective or contraindicated, as well as in
prove the clinical condition in none of the three patients, CGN unrelated to HCV infection, immunosuppressive
even though a clear reduction of HCV RNA serum con- therapy with or without plasmapheresis still maintains
centration could be observed in two of them. In contrast, an important role [1, 21, 23]. With regard to antiviral
4 weeks of combination therapy caused persistent disap- therapy, it is possible that, over the next few years, the
pearance of HCV viremia followed by clinical and bio- combination of peginterferon-alpha plus ribavirin, may
chemical response. It is well known that, in patients with prove more efficacious than the classic combination ther-
chronic hepatititis C, the HCV genotype is one of the apy in HCV-related CGN, as reported in chronic hepati-
most important factors conditioning the results of antiviral tis [24]. Therefore, further studies in larger and heteroge-
therapy [13, 18]. Thus, it is likely that the presence of neous groups of patients are needed to establish the
genotype 2 in all our patients may have fostered a sustained optimal treatment for HCV-related CGN.
virologic response. A rapid and marked improvement in
clinical signs was observed in all patients. Although the ACKNOWLEDGMENT
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